Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study.

Vincent Ka Chun YanEric Yuk Fai WanXuxiao YeAnna Hoi Ying MokFrancisco Tsz Tsun LaiCeline Sze Ling ChuiXue LiCarlos King Ho WongPhilip Hei LiTiantian MaSimon QinChak Sing LauIan Chi Kei WongEsther Wai Yin Chan

Published in: Emerging microbes & infections (2023)

Significant risk reduction against COVID-19-related hospitalization and mortality after CoronaVac or BNT162b2 vaccination was observed for >240 and >120 days after second and third doses compared to unvaccinated, despite significant waning over time. Timely administration of booster doses could provide higher levels of protection.

Keyphrases

coronavirus disease
sars cov
risk factors
systematic review
cardiovascular events
randomized controlled trial
respiratory syndrome coronavirus
drug induced
type diabetes
coronary artery disease